Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
Wellvone 750 mg/5 ml oral suspension.
| Pharmaceutical Form |
|---|
|
Oral suspension. Wellvone oral suspension is a bright yellow liquid. |
Each 5 ml of oral suspension contains 750 mg atovaquone.
Excipient with known effect: Each 5 ml of oral suspension contains 50.66 mg benzyl alcohol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Atovaquone |
Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III). |
| List of Excipients |
|---|
|
Benzyl alcohol |
A 240 ml high density polyethylene bottle with child resistant polypropylene closure, containing 226 ml of atovaquone suspension.
A double ended measuring spoon (polypropylene) is included, however, only 5 ml end (larger end) of the measuring spoon must be used.
Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
PL 10949/0271
Date of first authorisation: 25 March 1997
Date of latest renewal: 21 May 2006
| Drug | Countries | |
|---|---|---|
| WELLVONE | Australia, Estonia, Spain, France, Netherlands, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
